1970-73 ,Bachelor equiv.) in Biology from
Anhui Normal University, 1973-78, Lecturer in Medical
Microbiology, Benpu Medical College
1978-1980, for Master in Academia Sinica, 1980-1985,
Ph.D in Beatson Institute for Cancer Research, UK,
1985-1990, P.I, Associated Professor, Shanghai Inst of Cell Biology, Academia Sinica,
1990-June,2001, Senior scientist, P.I, in three academic and one Biotech firm in UK.

Since June, 2001
P.I of the Cancer Epigenetics and Gene Therapy group,
The State-key Laboratory for Oncogenes and Related Genes,
Shanghai Cancer Institute, Shanghai Jiaotong University, LN2200/25,
Xietu Road, Shanghai 200032, China
Email:zhujingde@sh163.net, @yahoo.com, Tel/Fax: 86-21 64224285

The researches in Jingde Zhu’s group are supported by both central and local governments in China as well as the European 6th Frame program. Dr. Zhu has published over sixty paper in the peer-review journals, including Cell, Nature, NAR, CCR, Oncogene, JBC, Cancer Gene Therapy, Cell Research, and etc. He is the inventor of one approved US patent and one filed US PCT as well as of four approved and two filed patents in China.

His team is actively compiling the human methylome in both health and disease states with a MBD mediated capture method (effectively fractionation the DNA fragments in mammalian genome according to the methylation density). Currently, more than ten collaborative projects are ongoing between Dr. Zhu’s team and the top researchers at home and abroad. Furthermore, three collaborative works on the sequence level of DNA methylomes are under review in the high profile journals at the moment. A large panel of the altered DNA methylation targets specific to each of three common types of solid tumors in China, including hepatocellular carcinoma, bladder cancer and lung cancer have been established, laying a solid foundation for the both basic and translation researches of cancer. The special emphases of the activities in Dr. Zhu’s team have been devoted to the clinical utility of DNA methylation as biomarkers for cancer detection. Two assay development activities are ongoing concerning DNA methylation profiling of the urine sediments in bladder cancer as well as of plasma DNA for the non-small cell lung cancer.

Since 2003, Dr. Zhu has been invited to speak in over fifty international conferences and many home meeting. He organized four international conference

1、“The First International Biomedical Frontier Workshop of Ovarian Cancer”， 20th, April, 2005, Shanghai, China
2、The 1st Shanghai Symposium of Epigenetics in Development and Diseases，23-25, Oct. 2003,
3、The 2nd Shanghai Symposium of Epigenetics in Development and Diseases/the 3rd Annual Meeting of Asia Epigenome Alliance, Shanghai, July 3-7, www.bioon.com/shanghaiepigeneticssymposium200807
4、The Sino-UK Workshop of the Frontier Biomedical Research, Shanghai, Oct, 26, China (http://www.bioevent.cn/meetingHome.asp?meetingid=50)

Specialty and Research Field of Interest:
1.Cancer Epigenetics.2. Epigenomics and 3. anit-cancer Gene Therapy

The Academic position:
The member of The AACR Epigenome Task Force Committee, USA (29 members in total)
The member of The Asian Epigenome Network (4 members in total)
The member of the grant review panel of UICC;
The member of the grant review panel of Research Grants Council (RGC) of Hong Kong
The member of the standing committee of the biotherapy in Chinese Association of Cancer Research;
The editor of Genome Medicine, Cancer Letter Cell Research, Journal of Genetics and Genomics and five other biomedical journals in China；

Recent Publications(since 2007):
[1-13]:
1. Zhu, J. and X. Yao, Use of DNA methylation for cancer detection: Promises and challenges. Int J Biochem Cell Biol, 2009. 41(1): p. 147-154.
2.Sun, J., et al., Hypermethylated SFRP1, but none of other nine genes "informative" for western countries, is valuable for bladder cancer detection in Mainland China. J Cancer Res Clin Oncol, 2009. 135(12): p. 1717-27.
3.Shi, Y., et al., A Sino-British frontier workshop of cancer biology. Cell Death Differ, 2009. 16(4): p. 648-50.
4.Lin, Q., et al., RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol, 2009. 135(12): p. 1675-84.
5.Yang, Y., et al., Phosphorylation of HsMis13 by Aurora B kinase is essential for assembly of functional kinetochore. J Biol Chem, 2008. 283(39): p. 26726-36.
6.Wu, Y., et al., A stringent dual control system overseeing transcription and activity of the Cre recombinase for the liver-specific conditional gene knock-out mouse model. J Genet Genomics, 2008. 35(7): p. 431-9.
7.The American Association for Cancer Research Human Epigenome Task Force and the European Union and S.A.B. Network of Excellence, Moving AHEAD with an international human epigenome project. Nature, 2008. 454(7205): p. 711-5.
8.Huang, Z.H., et al., Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol, 2008. 134(10): p. 1129-1134.
9.Fei, Q., et al., Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Biochim Biophys Sin (Shanghai), 2008. 40(6): p. 466-77.
10.Du, J., et al., The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability. Oncogene, 2008. 27(29): p. 4107-14.
11.Zhang, A.P., et al., The DNA methylation profile within the 5'-regulatory region of DRD2 in discordant sib pairs with schizophrenia. Schizophr Res, 2007. 90(1-3): p. 97-103.
12.Yu, J., et al., A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res, 2007. 13(24): p. 7296-304.
13. Huang, J., et al., Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis, 2007. 28(5): p. 1094-103.

Research Support:
International Funding: European 6th Frame Program
National Funding: 863, 973 and NSFC

Local Government’s Funding: Shanghai Municipal Government, and Philips Foundation